Menu

Presympto

"Detection before disease"

header photo

Applications

Presympto is focused on creating in vitro diagnostic and imaging tests for Alzheimer’s disease and other neurodegenerative diseases. Though increasingly prevalent, Alzheimer’s disease is currently a “diagnosis of exclusion” as disease progression rules out other potential causes. Our goal is to use Presympto’s unique technology, which detects the sequence and the conformation of amyloid proteins, to create sensitive and specific detection methods that allow early stage diagnosis and disease progression monitoring. All of Presympto’s peptide formulations have been generated internally, leveraging the company’s peptide chemistry and our understanding of protein misfolding to create Pronucleon™ diagnostic probes.